Spinal Muscular Atrophy (SMA) in Babies
The short answer
Spinal muscular atrophy (SMA) is a genetic neuromuscular disease that causes progressive muscle weakness by affecting motor neurons in the spinal cord. It affects about 1 in 6,000 to 10,000 births. SMA is now included in newborn screening in many states, enabling pre-symptomatic treatment. Revolutionary gene therapies (Zolgensma, nusinersen/Spinraza, risdiplam/Evrysdi) have dramatically changed the prognosis, especially when treatment begins before symptoms appear.
By Age
What to expect by age
SMA Type 1, the most severe form, typically presents in the first 6 months of life. Early signs include severe hypotonia (floppy baby), weak cry, difficulty feeding and swallowing, reduced spontaneous movement, and a characteristic "frog-leg" posture. Babies may have a bell-shaped chest due to weak intercostal muscles and breathe primarily with their diaphragm. With the addition of SMA to the newborn screening panel, many babies are now diagnosed before symptoms appear, allowing for immediate treatment.
Untreated babies with SMA Type 1 progressively weaken during this period, losing the ability to hold their head up and eventually developing breathing and swallowing difficulties. However, babies who are treated pre-symptomatically with gene therapy (onasemnogene abeparvovec/Zolgensma) or other therapies (nusinersen/Spinraza or risdiplam/Evrysdi) are achieving milestones that were previously unimaginable — many are sitting and even standing. Early treatment is truly transformative.
SMA Type 2 typically presents between 6-18 months. These babies may have achieved the ability to sit independently but never achieve independent walking. Signs include progressively weaker legs, hand tremor, and difficulty transitioning between positions. Treated babies with SMA Type 1 who received early intervention continue to make progress. Respiratory monitoring and nutritional support remain important aspects of care.
Ongoing treatment and multidisciplinary care are essential. Physical therapy, respiratory support, nutritional management, and orthopedic monitoring help maintain function and quality of life. The treatment landscape for SMA has been revolutionized — children who would previously have had very limited prognoses are now walking, talking, and thriving. The earlier treatment begins relative to symptom onset, the better the outcomes.
What Should You Do?
When to take action
- Your baby's newborn screening was normal for SMA
- Your baby has normal muscle tone, can lift their head, and moves all four limbs equally
- Your baby was diagnosed with SMA through newborn screening and is on treatment with good developmental progress
- Your baby has a mild form (SMA Type 3) with subtle weakness that is being managed
- Your baby seems unusually floppy, has a weak cry, or is not moving their arms and legs as much as expected
- Your baby cannot hold their head up by 4 months or seems to be getting weaker rather than stronger
- You received an abnormal SMA newborn screening result — follow up immediately for confirmatory genetic testing
- Your baby has progressive muscle weakness with increasing difficulty breathing or swallowing — SMA can cause respiratory failure, and early treatment is critical
- Your newborn screening is positive for SMA — contact the genetics or neuromuscular team immediately, as treatment within the first weeks of life produces the best outcomes
Sources
Related Resources
Related Medical Concerns
My Baby's Head Shape Looks Abnormal
Many babies develop temporary head shape irregularities that are completely normal. A cone-shaped head from vaginal delivery reshapes within days. Mild positional flattening (plagiocephaly) from sleeping on the back is very common and usually improves with repositioning and tummy time. However, head shape changes involving ridges, a persistently bulging fontanelle, or rapid head growth changes should be evaluated to rule out craniosynostosis.
Achondroplasia (Dwarfism) in Babies
Achondroplasia is the most common form of short-limbed dwarfism, affecting about 1 in 15,000 to 40,000 births. It is caused by a mutation in the FGFR3 gene and is usually apparent at birth with characteristic features including short limbs, a larger head, and a prominent forehead. Intelligence is normal. With monitoring for specific complications and supportive care, children with achondroplasia lead full, active, and independent lives.
Adenoid Hypertrophy and Breathing
Adenoids are lymphoid tissue located behind the nose that help fight infection in young children. When adenoids become enlarged (adenoid hypertrophy), they can block the nasal airway, causing chronic mouth breathing, snoring, nasal speech, and sleep-disordered breathing. Enlarged adenoids are most common between ages 2-7 and are a leading cause of obstructive sleep apnea in young children. Treatment ranges from watchful waiting and nasal steroids to surgical removal (adenoidectomy) if breathing or sleep is significantly affected.
Air Quality and Baby Health
Babies and young children are more vulnerable to air pollution than adults because they breathe faster, their lungs are still developing, and they spend more time close to the ground where some pollutants concentrate. The EPA recommends keeping babies indoors when the Air Quality Index (AQI) exceeds 100 (orange level). During wildfire smoke events, keep windows closed, use air purifiers with HEPA filters, and monitor your child for coughing, wheezing, or difficulty breathing. Long-term exposure to air pollution can affect lung development.
Altitude Sickness in Babies
Babies and toddlers can experience altitude sickness when traveling above 5,000-8,000 feet (1,500-2,500 meters). Symptoms are harder to recognize in infants because they cannot describe how they feel. Watch for unusual fussiness, poor feeding, disrupted sleep, vomiting, and fast breathing. Gradual ascent is the best prevention. Most pediatricians recommend avoiding sleeping at very high altitudes (above 8,000 feet) with infants when possible, and descending immediately if symptoms appear.
Amblyopia (Lazy Eye) Treatment Timing
Amblyopia (lazy eye) is the most common cause of vision loss in children, affecting 2-3% of the population. It occurs when one eye develops weaker vision because the brain favors the other eye. Early detection and treatment are critical because the visual system is most responsive to treatment during early childhood. Treatment is most effective when started before age 7, though improvement is possible at older ages. Treatment options include patching the stronger eye, atropine eye drops, glasses, or a combination.